Comparative Pharmacology
Head-to-head clinical analysis: WEGOVY versus WEGOVY HD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: WEGOVY versus WEGOVY HD.
WEGOVY vs WEGOVY HD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Semaglutide, a GLP-1 receptor agonist, increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and reduces appetite via central GLP-1 receptor activation.
WEGOVY (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and promotes satiety.
Subcutaneous injection 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg once weekly for 4 weeks, then 1 mg once weekly for 4 weeks, then 1.7 mg once weekly for 4 weeks, then maintenance 2.4 mg once weekly.
Subcutaneous injection once weekly. Initiate at 0.25 mg weekly for 4 weeks, then increase to 0.5 mg weekly for 4 weeks, then 1 mg weekly for 4 weeks, then 1.7 mg weekly for 4 weeks, then maintain at 2.4 mg weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 1 week (6–8 days), supporting once-weekly subcutaneous dosing.
Terminal elimination half-life approximately 165 hours (≈7 days), supporting once-weekly dosing.
Primarily renal; approximately 97% of the dose is excreted unchanged in urine, with less than 3% in feces via biliary excretion.
Primarily renal elimination of intact peptide; ~47% excreted unchanged in urine, remainder via fecal/biliary routes (≈38%).
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist